JP2021528047A5 - - Google Patents
Info
- Publication number
- JP2021528047A5 JP2021528047A5 JP2020562110A JP2020562110A JP2021528047A5 JP 2021528047 A5 JP2021528047 A5 JP 2021528047A5 JP 2020562110 A JP2020562110 A JP 2020562110A JP 2020562110 A JP2020562110 A JP 2020562110A JP 2021528047 A5 JP2021528047 A5 JP 2021528047A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable region
- chain variable
- antigen
- polypeptide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862668427P | 2018-05-08 | 2018-05-08 | |
| US62/668,427 | 2018-05-08 | ||
| US201862754207P | 2018-11-01 | 2018-11-01 | |
| US62/754,207 | 2018-11-01 | ||
| US201962787815P | 2019-01-03 | 2019-01-03 | |
| US62/787,815 | 2019-01-03 | ||
| PCT/US2019/029888 WO2019217145A1 (en) | 2018-05-08 | 2019-04-30 | Anti-dll3 antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528047A JP2021528047A (ja) | 2021-10-21 |
| JP2021528047A5 true JP2021528047A5 (enExample) | 2022-05-02 |
| JP7455388B2 JP7455388B2 (ja) | 2024-03-26 |
Family
ID=68467536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562110A Active JP7455388B2 (ja) | 2018-05-08 | 2019-04-30 | 抗ｄｌｌ３抗体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US12037391B2 (enExample) |
| EP (1) | EP3790586A4 (enExample) |
| JP (1) | JP7455388B2 (enExample) |
| KR (1) | KR102922314B1 (enExample) |
| CN (2) | CN118146372A (enExample) |
| AU (1) | AU2019267349B2 (enExample) |
| BR (1) | BR112020021280A2 (enExample) |
| CA (1) | CA3097193A1 (enExample) |
| IL (1) | IL278466B2 (enExample) |
| MX (1) | MX2020011914A (enExample) |
| SG (1) | SG11202009772PA (enExample) |
| WO (1) | WO2019217145A1 (enExample) |
| ZA (1) | ZA202006318B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021012336A (es) * | 2019-04-08 | 2021-11-12 | Phanes Therapeutics Inc | Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos. |
| JP7900284B2 (ja) * | 2019-12-17 | 2026-08-04 | フェインズ セラピューティクス，インコーポレーテッド | 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用 |
| WO2022170305A1 (en) * | 2021-02-05 | 2022-08-11 | Phanes Therapeutics, Inc. | Bispecific antibodies with charge pairs and uses thereof |
| US20240239878A1 (en) * | 2021-05-08 | 2024-07-18 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Binding molecule against dll3 and use thereof |
| JP7892050B2 (ja) * | 2021-07-30 | 2026-07-17 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | 抗ｄｌｌ３抗体とその製造方法、その薬物複合体及び使用 |
| CN116271079B (zh) * | 2021-07-30 | 2025-11-14 | 上海复旦张江生物医药股份有限公司 | 一种抗dll3抗体及其制备方法、其药物偶联物和应用 |
| AU2022345323A1 (en) * | 2021-09-17 | 2024-03-28 | WuXi Biologics Ireland Limited | D3-binding molecules and uses thereof |
| TW202346346A (zh) * | 2021-12-23 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途 |
| CN114292334B (zh) * | 2021-12-24 | 2023-11-17 | 杭州贤至生物科技有限公司 | 抗可替宁特异性抗体、质粒载体及方法 |
| CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
| CN116789836B (zh) * | 2023-08-14 | 2024-01-05 | 浙江时迈药业有限公司 | 针对dll3的抗体及其用途 |
| WO2026046399A1 (en) * | 2024-09-02 | 2026-03-05 | Primelink Biotherapeutics (Shenzhen) Co., Ltd. | Anti-dll3 antibodies and use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2844519A1 (fr) * | 2002-09-17 | 2004-03-19 | Bio Merieux | Proteine recombinante chimerique et diagnostic in vitro |
| EP1973945A4 (en) | 2006-01-16 | 2009-11-18 | Compugen Ltd | NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND METHOD FOR THEIR APPLICATION IN DIAGNOSIS |
| BRPI1012085A2 (pt) * | 2009-08-24 | 2019-09-24 | Fraunhofer Ges Forschung | anticorpo de resistência de plantas mediado por fusão contra oomycota |
| CA2775573A1 (en) * | 2009-10-09 | 2011-04-14 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her 3 antibodies |
| PL2530091T3 (pl) | 2010-01-29 | 2018-08-31 | Chugai Seiyaku Kabushiki Kaisha | Przeciwciało przeciwko dll3 |
| CA2799746C (en) | 2010-05-17 | 2020-11-24 | Sai Reddy | Rapid isolation of monoclonal antibodies from animals |
| CN104520324A (zh) | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| ES2731681T3 (es) | 2013-02-22 | 2019-11-18 | Abbvie Stemcentrx Llc | Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos |
| CA2922544A1 (en) * | 2013-08-28 | 2015-03-05 | Stemcentrx, Inc. | Engineered anti-dll3 conjugates and methods of use |
| EP3107576A4 (en) | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| MX2017006167A (es) * | 2014-11-12 | 2018-03-23 | Siamab Therapeutics Inc | Compuestos que interactúan con glicanos y métodos de uso. |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| MA41645A (fr) | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
| CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| US20190048094A1 (en) * | 2016-02-24 | 2019-02-14 | Oncomed Pharmaceuticals, Inc. | Redirecting immune responses |
| EP3458050A1 (en) | 2016-05-20 | 2019-03-27 | Abbvie Stemcentrx LLC | Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition |
| JOP20190009A1 (ar) * | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| MX2020001309A (es) | 2017-08-02 | 2020-08-20 | Phanes Therapeutics Inc | Anticuerpos anti-cd47 y sus usos. |
| JP7314146B2 (ja) | 2017-12-28 | 2023-07-25 | 中外製薬株式会社 | 細胞傷害誘導治療剤 |
| US20190225685A1 (en) | 2018-01-24 | 2019-07-25 | Abbvie Stemcentrx Llc | Anti-dll3 antibody drug conjugates and methods of use |
| US20220025037A1 (en) | 2018-04-03 | 2022-01-27 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting dll3, and use thereof |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| CN119306844A (zh) | 2018-09-25 | 2025-01-14 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
-
2019
- 2019-04-30 AU AU2019267349A patent/AU2019267349B2/en active Active
- 2019-04-30 MX MX2020011914A patent/MX2020011914A/es unknown
- 2019-04-30 CN CN202410395728.2A patent/CN118146372A/zh active Pending
- 2019-04-30 JP JP2020562110A patent/JP7455388B2/ja active Active
- 2019-04-30 CA CA3097193A patent/CA3097193A1/en active Pending
- 2019-04-30 CN CN201980031386.3A patent/CN112584860B/zh active Active
- 2019-04-30 SG SG11202009772PA patent/SG11202009772PA/en unknown
- 2019-04-30 EP EP19800438.4A patent/EP3790586A4/en active Pending
- 2019-04-30 WO PCT/US2019/029888 patent/WO2019217145A1/en not_active Ceased
- 2019-04-30 KR KR1020207034344A patent/KR102922314B1/ko active Active
- 2019-04-30 BR BR112020021280-6A patent/BR112020021280A2/pt unknown
- 2019-04-30 US US15/733,747 patent/US12037391B2/en active Active
-
2020
- 2020-10-12 ZA ZA2020/06318A patent/ZA202006318B/en unknown
- 2020-11-03 IL IL278466A patent/IL278466B2/en unknown
-
2024
- 2024-06-04 US US18/733,287 patent/US12325745B2/en active Active
-
2025
- 2025-04-29 US US19/193,538 patent/US20250257127A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514664A5 (enExample) | ||
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2024531409A5 (enExample) | ||
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| CN101970497B (zh) | 抗‑EpCAM抗体及其用途 | |
| JP2021516057A5 (enExample) | ||
| CN112969476B (zh) | 多特异性蛋白分子 | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2021524244A5 (enExample) | ||
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| JP2021526022A5 (enExample) | ||
| JP2023546743A5 (enExample) | ||
| CN116731180A (zh) | 抗ror1抗体及其制备和使用方法 | |
| JP2020528750A5 (enExample) | ||
| JP2022526420A5 (enExample) | ||
| CN112513094A (zh) | 结合人her2的抗体、其制备方法和用途 | |
| JP2013502913A5 (enExample) | ||
| JP2021517459A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| BR112020001657A2 (pt) | Anticorpo contra cd147 humana, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, uso do anticorpo ou do fragmento de ligação a antígeno,polinucleotídeo, vetor de expressão, célula hospedeira, método para produzir o anticorpo ou o fragmento de ligação a antígeno do mesmo, para prognosticar aresponsividade ao tratamento contra o câncer e para selecionar sujeitos para o tratamento contra o câncer, kit para determinar a responsividade ao tratamento contra o câncer, complexo de anticorpo-fármaco, e, anticorpo biespecífico | |
| JP2022526841A5 (enExample) | ||
| CN110698558B (zh) | 一种tpbg抗体及其制备方法、其偶联物和应用 | |
| JP2021512652A5 (enExample) | ||
| JP2024528935A5 (enExample) |